Vanda Pharmaceuticals Inc. filed a Form 8-K with the SEC on October 28, 2026, reporting results of operations and financial condition for the quarter ended September 30, 2026, and announcing an accompanying earnings conference call and press release.

Key Highlights

  • Reporting period: The disclosure covers the quarter ended September 30, 2026.
  • Press release furnished: A press release dated October 28, 2026, was furnished as Exhibit 99.1 and incorporated by reference into the filing.
  • Conference call: Vanda disclosed it is holding an earnings call regarding results of operations and financial condition on October 28, 2026.
  • Forward-looking statements: Vanda cautioned that statements made during the earnings call include forward-looking statements subject to risks and uncertainties, and that "no assurance can be given that the actual results or developments anticipated by Vanda will be realized."
  • Signed by: The filing was signed by Daniel McGuire, Senior Vice President, General Counsel and Secretary.

Vanda Pharmaceuticals Furnishes Q3 2026 Earnings Press Release and Conference Call Details

According to the filing, Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) submitted a current report on Form 8-K on October 28, 2026, under Item 2.02 (Results of Operations and Financial Condition). The company disclosed that it issued a press release and held a conference call on the same date concerning its financial results for the quarter ended September 30, 2026. The full text of the press release was furnished as Exhibit 99.1 and incorporated by reference into the report.

The filing noted that various statements to be made during the earnings call are "forward-looking statements" under the securities laws, including statements regarding Vanda's commercial products, plans and opportunities, as well as products in development and related clinical development, regulatory timelines, and commercial potential. The company identified words such as "believe," "expect," "anticipate," "estimate," "intend," "plan," "project," "target," "goal," "likely," "will," "would," and "could" as indicators of forward-looking statements.

Vanda stated that forward-looking statements are "based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties," and cited factors including assumptions regarding business strength in the U.S. and the ability to complete clinical development and obtain regulatory approvals for pipeline products. The filing also specified that the information in Item 2.02 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference in other filings except as expressly set forth.

What Was Disclosed

Vanda Pharmaceuticals filed an 8-K on October 28, 2026, furnishing a press release and disclosing an earnings conference call covering the quarter ended September 30, 2026. The filing included forward-looking statement cautionary language and was signed by General Counsel Daniel McGuire.